The P-III trial investigates the safety, efficacy and tolerability of Ajovy (225mg, once-monthly for 3mos. or 675mg single dose, once-quarterly, SC) injection vs PBO as a treatment of Chinese patients (n=365, 18-70yrs.) with episodic or chronic migraine
The study demonstrated a reduction in the monthly migraine days and reached the 2EPs of measures for early efficacy within the first month, responder rate analysis (50% reduction of migraine days) & decreased use of acute headache medication over 3mos. post-initiation
The drug was well-tolerated without any emerging safety signals and the safety profile aligned with the prior P-III studies for treating migraine
Ref: Teva | Image: Teva
Related News:- Teva Presents P-IV (UNITE) Study Results of Ajovy (fremanezumab) for Migraine and Major Depressive Disorder at World Congress of Neurology
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
